

REMARKS

I. Summary of the Office Action

1. The Office Action rejected claims 1-27 under 35 U.S.C. §112, 2nd paragraph for allegedly using the term “amplification reagent” in a manner inconsistent with its art-accepted meaning.

2. The Office Action rejected claims 1-27 under 35 U.S.C. §101 for allegedly claiming the identical invention as prior U.S. Patent 6,203,989.

II. Response to the Office Action

Rejection of claims 1-27 under 35 U.S.C. §112, 2nd paragraph

The Office Action maintains the allegation that the use of the term “amplification reagent” in the claims is repugnant to the usual meaning of the term in the art because,

“in the biotechnology art, specifically in the class and subclass in which this application has been placed, (435/6), the accepted and well-known meaning of “amplification reagent” is a reagent that aids in the amplification of nucleic acids.”

Applicants respectfully disagree with the ground of rejection and submit that the rejection is due to a continued interpretation of the claims not made in light of the specification. It is respectfully pointed out that the Manual of Classification is not a lexicography guide, however, in the interest of advancing prosecution in the instant application, the claims have been amended to recite “signal amplification reagent.” While the amendment does not alter the scope of the claim when read in light of the specification, the addition of the term “signal” more clearly defines within the body of the claims exactly what the reagent is amplifying. The term “signal amplification” is an art-accepted term for increasing the signal intensity at a reaction site to aid in the identification of the reaction. This is evidenced by the disclosure of Stears *et al* (Physiol. Genomics, 3:93-99 (2000); attached as Appendix B), particularly in the abstract where it is stated

“[t]o improve signal detection on cDNA microarrays, we adapted a fluorescent oligonucleotide dendrimeric signal amplification system to microarray technology” (emphases added).

Accordingly, as used herein, the term “signal amplification reagent” is used in a manner consistent with an art accepted meaning to denote a reagent which “permits the detectable signal to be enhanced and more easily detectable” (page 3, lines 23-24, of the instant specification for example). Applicants respectfully request withdrawal of the ground of rejection.

Rejection of claims 1-27 under 35 U.S.C. §101 for claiming the same invention as claims 1-27 of U.S. Patent 6,203,989

The Office Action maintains that the claims are drawn to the identical invention as claims 1-27 of the ‘989 patent and therefore are subject to the double patenting provisions of 35 U.S.C. § 101. Applicants respectfully disagree with this position. In order for a claimed invention to be considered “the same” as another claimed invention and be subject to a statutory double patenting rejection, the claimed inventions must be identical. This is not the case in regard to the instantly claimed invention *versus* the invention claimed in the ‘989 patent. The instant claims require the presence of a “signal amplification reagent” in each of the base claims 1 (step c) and 23 (step d). In contrast, none of the claims of the ‘989 patent recite a “signal amplification reagent” as a limitation. In the further explanation of the grounds of rejection presented, the Office Action states that an adequate test for statutory double patenting is whether there is an embodiment that falls within the scope of one claim but not the other. The Office Action provides the example of “halogen” and “chlorine” and states that a claim reciting halogen “is not identical to or substantively the same as a claim reciting” chlorine because “halogen is broader than chlorine.” It is respectfully submitted that the instant application mirrors this example set forth in the Office Action, rather than the alternative example of “36 inches” versus “3 feet,” as the term “reagent” recited in the claims of the ‘989 patent is clearly broader than the term “signal amplification reagent” as used in the present claims. Further, the Office Action has erroneously read the limitations of dependent claims into the base claims, as evidenced by the statement, “the term ‘reagent’ is used to mean an antibody, or DNA matrix, or another element which will bind

the reagent.” Applicants respectfully point out that none of those “elements” are recited in the base claim and therefore cannot be considered limitations thereof. Accordingly, Applicants assert that the claims are not drawn to the same invention, as the statute requires, and respectfully request withdrawal of the improper ground of rejection.


Conclusion.

In view of the foregoing remarks, the Applicants respectfully request withdrawal of all outstanding rejections and early notice of allowance to that effect. If the Examiner believes that allowance of this application may be expedited by a telephonic interview, she is encouraged to contact the undersigned.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP


Enrique B. Longton
Reg. No. 47,304

Dated: July 28, 2003

CUSTOMER NO. 000033522
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Ave., N.W.
Washington, DC 20004
202.739.3000 (voice)
202.739.3001 (fax)